MedTrace Logo

School Based Malaria Control in Ugandan Schoolchildren

NCT01231880 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 740

Last updated 2013-05-23

No results posted yet for this study

Summary

The investigators hypothesize that schoolchildren treated with IPT using DP over one year of follow-up will have a different risk of clinical malaria compared to those treated with placebo.

Conditions

Interventions

DRUG

Four monthly IPT with dihydroartemisinin Piperaquine (DP)

Given every 4 months (once a school term)

DRUG

Monthly IPT using DP

Given every month

DRUG

Placebo given every month

No active ingredient

Sponsors & Collaborators

  • Bill and Melinda Gates Foundation

    collaborator OTHER

  • Makerere University

    lead OTHER

Principal Investigators

  • Joaniter I Nankabirwa, MSc CEB · Makerere University Kampala

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
6 Years
Max Age
14 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2011-02-28
Primary Completion
2012-09-30
Completion
2012-09-30

Countries

  • Uganda

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01231880 on ClinicalTrials.gov